Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Novelos Therapeutics Inc. Stories

2012-04-24 02:30:08

MADISON, Wis., April 24, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has successfully completed the first cohort in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with advanced non-small...

2012-04-03 02:27:32

MADISON, Wis., April 3, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that three scientific posters based on research conducted by Jamey Weichert, Ph.D., and his colleagues are being presented at the American Association for Cancer Research (AACR) annual meeting in Chicago. These presentations describe findings in animal and cellular model systems that illustrate Novelos'...

2012-03-15 07:30:00

MADISON, Wis., March 15, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading medical oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with primary or...

2012-02-16 07:30:00

MADISON, Wis., Feb. 16, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, announced that today its common stock will begin trading on OTCQX, the top tier of the OTC market designated for OTC companies that meet standards established by the OTC Market Group. Novelos' trading symbol, "NVLT", will remain the same. Investors may find current financial disclosure and Real-Time Level 2 quotes for...

2012-02-16 06:00:00

NEW YORK, Feb. 16, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that Novelos Therapeutics, Inc. (OTCQX: NVLT), a U.S.-based pharmaceutical company, is now trading on the OTC market's highest tier, OTCQX®. (Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ) Novelos began trading today on the OTC market's prestigious tier, OTCQX. U.S....

2012-01-17 07:30:00

MADISON, Wis., Jan. 17, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has enrolled the first patient in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound (131)I-CLR1404 (HOT) in cancer patients with advanced solid tumors. Details of the trial design are available on www.clinicaltrials.gov ID:...

2011-12-07 07:30:00

MADISON, Wis., Dec. 7, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the closing of an underwritten public offering of 10,081,667 units at $0.60 per unit for proceeds, net of underwriting discounts and commissions, of $5,747,000. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. The warrants have an exercise price...

2011-12-01 08:21:00

MADISON, Wis., Dec. 1, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000. Each unit consists of one share of common stock and a warrant to purchase one share of common stock. The warrants will have an exercise price of $0.60 per share and a 5-year term. The...

2011-09-06 07:30:00

MADISON, Wis., Sept. 6, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 13th Annual Healthcare Conference on Monday, September 12, 2011. Mr. Palmin is scheduled to present at 4:05pm EDT in the Starlight Center. The event will be held September 11-13, at The Waldorf Astoria, 301...

2011-06-28 07:30:00

MADISON, Wis., June 28, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011, Judge Nathaniel M. Gorton allowed the defendants' motion to dismiss the putative federal securities fraud class action brought in the United States District Court for the District of Massachusetts in March 2010 entitled Boris Urman and Ramona McDonald v. Novelos Therapeutics, Inc....